Abstract
A comprehensive genetic screen reveals new cellular trafficking factors and linker-dependent requirements for antibody–drug conjugate (ADC) cytotoxicity. These new insights may guide the design of optimized ADCs.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have